AtaiBeckley Inc. Common Stock (ATAI)

Price$3.95

Value ScoreF

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-6.38%

Price vs S&P 500 (4W)-1.98%

VGM Score40.98

Market Capitalization$1.45B

All Metrics

Book Value / Share (Quarterly)$0.54

P/TBV (Annual)6.78x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)160.99%

Cash Flow / Share (Quarterly)$-0.31

Price vs S&P 500 (YTD)-11.58%

Net Profit Margin (TTM)-19019.44%

EPS (TTM)$-2.23

10-Day Avg Trading Volume5.73M

EPS Excl Extra (TTM)$-2.23

EPS (Annual)$-2.91

ROI (Annual)-297.49%

Net Profit Margin (5Y Avg)-28899.22%

Cash / Share (Quarterly)$0.63

Revenue Growth QoQ (YoY)-38.65%

ROA (Last FY)-225.49%

Revenue Growth TTM (YoY)86.72%

EBITD / Share (TTM)$-2.38

ROE (5Y Avg)-109.07%

Operating Margin (TTM)-18569.09%

Cash Flow / Share (Annual)$-0.31

P/B Ratio7.32x

P/B Ratio (Quarterly)6.50x

Net Income / Employee (Annual)$-6,667,100

EV / Revenue (TTM)404.57x

Net Interest Coverage (TTM)-40.12x

ROA (TTM)-268.96%

EPS Incl Extra (Annual)$-2.91

Current Ratio (Annual)11.74x

Quick Ratio (Quarterly)9.90x

3-Month Avg Trading Volume5.40M

52-Week Price Return59.27%

Revenue / Employee (TTM)$35,200

Tangible BV / Share (Quarterly)$0.54

P/S Ratio (Annual)355.65x

Asset Turnover (Annual)0.01x

52-Week High$6.75

Operating Margin (5Y Avg)-29988.13%

EPS Excl Extra (Annual)$-2.91

CapEx CAGR (5Y)182.88%

26-Week Price Return1.54%

Quick Ratio (Annual)11.56x

13-Week Price Return11.58%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.02x

Enterprise Value$1.41B

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$41,300

Pretax Margin (Annual)-16137.17%

Cash / Share (Annual)$0.70

3-Month Return Std Dev76.07%

Net Income / Employee (TTM)$-6,701,000

ROE (Last FY)-297.49%

Net Interest Coverage (Annual)-88.98x

EPS Basic Excl Extra (Annual)$-2.91

Receivables Turnover (TTM)0.05x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.23

Receivables Turnover (Annual)0.03x

ROI (TTM)-363.40%

P/S Ratio (TTM)416.93x

Pretax Margin (5Y Avg)-27255.25%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$0.60

Price vs S&P 500 (52W)34.91%

Year-to-Date Return-3.42%

5-Day Price Return-18.05%

EPS Normalized (Annual)$-2.91

ROA (5Y Avg)-84.65%

Net Profit Margin (Annual)-16142.02%

Month-to-Date Return-12.80%

Cash Flow / Share (TTM)$-0.41

EBITD / Share (Annual)$-2.81

Operating Margin (Annual)-15582.27%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-103.88%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.23

P/TBV (Quarterly)6.59x

P/B Ratio (Annual)6.70x

Pretax Margin (TTM)-19017.26%

Book Value / Share (Annual)$0.61

Price vs S&P 500 (13W)3.33%

Beta1.68x

Revenue / Share (TTM)$0.01

ROE (TTM)-366.49%

52-Week Low$2.00

vGradeF

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.08est. -0.10

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.21

4.20

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ATAIAtaiBeckley Inc. Common Stock	F	C	C	$3.95
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

AtaiBeckley Inc is a clinical-stage biopharmaceutical company developing novel therapies for psychiatric disorders, with a focus on rapid-acting and convenient treatment options. The company's Phase 2 pipeline includes three candidates: BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, VLS-01 (DMT buccal film) for treatment-resistant depression and social anxiety disorder, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. These programs address significant unmet medical needs in mental health treatment.